New drug aims to smooth out Parkinson's motor swings
NCT ID NCT05766813
First seen May 30, 2026 · Last updated Jun 14, 2026 · Updated 5 times
Summary
This study tested an experimental drug called lenrispodun in 79 people with Parkinson's disease who experience motor fluctuations (wearing off and involuntary movements). Participants took the drug or a placebo alongside their regular Parkinson's medications. The goal was to see if lenrispodun could improve daily motor control and reduce troublesome symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Phoenix, Arizona, 85013, United States
-
Clinical Site
Scottsdale, Arizona, 85251, United States
-
Clinical Site
Irvine, California, 92697, United States
-
Clinical Site
Loma Linda, California, 92354, United States
-
Clinical Site
Altamonte Springs, Florida, 32714, United States
-
Clinical Site
Boca Raton, Florida, 33486, United States
-
Clinical Site
Coral Springs, Florida, 33067, United States
-
Clinical Site
Doral, Florida, 33178, United States
-
Clinical Site
Hallandale, Florida, 33009, United States
-
Clinical Site
Maitland, Florida, 32751, United States
-
Clinical Site
Miami, Florida, 33136, United States
-
Clinical Site
Ocala, Florida, 34470, United States
-
Clinical Site
Orlando, Florida, 32804, United States
-
Clinical Site
Orlando, Florida, 32825, United States
-
Clinical Site
Port Orange, Florida, 32127, United States
-
Clinical Site
Tampa, Florida, 33612, United States
-
Clinical Site
Augusta, Georgia, 30912, United States
-
Clinical Site
Decatur, Georgia, 30030, United States
-
Clinical Site
Kansas City, Kansas, 66160, United States
-
Clinical Site
Farmington Hills, Michigan, 48334, United States
-
Clinical Site
Golden Valley, Minnesota, 55427, United States
-
Clinical Site
Albany, New York, 12208, United States
-
Clinical Site
Rock Hill, South Carolina, 29732, United States
-
Clinical Site
Franklin, Tennessee, 37067, United States
-
Clinical Site
Memphis, Tennessee, 38157, United States
-
Clinical Site
Austin, Texas, 78746, United States
-
Clinical Site
Dallas, Texas, 75243, United States
-
Clinical Site
Georgetown, Texas, 78628, United States
-
Clinical Site
Alexandria, Virginia, 22311, United States
-
Clinical Site
Falls Church, Virginia, 22042, United States
-
Clinical Site
Henrico, Virginia, 23233, United States
-
Clinical Site
Kirkland, Washington, 98034, United States
-
Clinical Site
Spokane, Washington, 99202, United States
-
Clinical Site
Crab Orchard, West Virginia, 25827, United States
-
Clinical Site
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.